Skip to main content

Advertisement

SpringerLink
Log in

Maternal mumps antibodies in a cohort of children up to the age of 1 year

  • Original Article
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

The duration of the presence of maternal mumps antibodies in a prospective cohort study is presented. Immunoglobulin G against mumps was portioned with a commercial ELISA test (Euroimmun® anti-mumps Virus AT ELISA, Germany) on samples from 213 mother–child pairs at seven time points between pregnancy and 12 months of age. Non-linear mixed models were used to model maternal antibody decay in infants. The model-based median time to loss of antibodies was 3.6 months. The median child-specific time to loss of antibodies in children of naturally immune women (3.8 months) and children of vaccinated women (2.4 months) differed significantly (p = 0.025). The log antibody level of the mother and the log birth weight were correlated with the duration of maternal antibodies in infants (p < 0.0001). Conclusion: Children of vaccinated women loose maternal mumps antibodies significantly earlier in life compared to children of naturally infected women. If early administration (<12 months) of the combined measles, mumps, and rubella vaccine is needed, maternal mumps antibodies are not expected to interfere with infant humoral vaccine responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Caceres VM, Strebel PM, Sutter RW (2000) Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. ClinInfectDis 31:110–119

    CAS  Google Scholar 

  2. Castilla J, Garcia Cenoz M, Barricarte A, Irisarri F, Nunez-Cordoba JM, Barricarte A (2007) Mumps outbreak in Navarre region, Spain, 2006–2007. Euro Surveillance 12:E070215–070211

    PubMed  Google Scholar 

  3. Celko A, Burianova B, Fedova D, Koza J, Zikmundova V, Zikmund V, Stribrny J (1985) Transplacental antibodies. Part III: Maternal antibodies against polioviruses, M. parotitidis and M. parainfluenzae. J Hyg Epidemiol Microbiol Immunol 29:193–199

    PubMed  CAS  Google Scholar 

  4. Centers for Disease Control and Prevention (2010) Update: mumps outbreak—New York and New Jersey, June 2009–January 2010. MMWR Morb Mortal Wkly Rep 59:125–129

    Google Scholar 

  5. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, Brown D, Ramsay ME (2007) Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 13:12–17

    PubMed  Google Scholar 

  6. Date AA, Kyaw MH, Rue AM, Klahn J, Obrecht L, Krohn T, Rowland J, Rubin S, Safranek TJ, Bellini WJ, Dayan GH (2008) Long-term persistence of mumps antibody after receipt of 2 measles–mumps–rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 197:1662–1668

    Article  PubMed  Google Scholar 

  7. Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, Hunt K et al (2008) Recent resurgence of mumps in the United States. N Engl J Med 358:1580–1589

    Article  PubMed  CAS  Google Scholar 

  8. deMoraesPinto MI, Almeida ACM, Kenj G, Filgueiras TE, Tobias W, Santos AMN, CarneiroSampaio MMS, Farhat CK, Milligan PJM, Johnson PM, Hart CA (1996) Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis 173:1077–1084

    Article  CAS  Google Scholar 

  9. Desgrandchamps D, Schaad UB, Glaus J, Tusch G, Heininger U (2000) Seroprevalence of IgG antibodies against measles, mumps and rubella in Swiss children during the first 16 months of life. SchweizMedWochenschr 130:1479–1486

    CAS  Google Scholar 

  10. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM (2003) Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 21:3398–3405

    Article  PubMed  CAS  Google Scholar 

  11. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM (2001) Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184:817–826

    Article  PubMed  CAS  Google Scholar 

  12. Gotlieb-Stematsky T, Meron I, Modan M, Sayar Y, Leventon-Kriss S, Fogel A, Gurewitz R, Insler V (1983) Viral antibodies in maternal and cord sera. MedMicrobiolImmunol(Berl) 172:67–74

    CAS  Google Scholar 

  13. Hartter HK, Oyedele OI, Dietz K, Kreis S, Hoffman JP, Muller CP (2000) Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. PediatrInfectDisJ 19:635–641

    CAS  Google Scholar 

  14. Hodes D, Brunell PA (1970) Mumps antibody: placental transfer and disappearance during the first year of life. Pediatrics 45:99–101

    PubMed  CAS  Google Scholar 

  15. Mumps Surveillance report 2010, Euvac.net (2011) http://ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=751. Accessed 11 Oct 2011

  16. Hukic M, Ravlija J, Dedeic Ljubovic A, Moro A, Arapcic S, Muller CP et al (2011) Ongoing large mumps outbreak in the Federation of Bosnia and Herzegovina, Bosnia and Herzegovina, December 2010 to July 2011. Euro Surveill 16(35)

  17. Kaaijk P, van der Zeijst B, Boog M, Hoitink C (2008) Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill 13

  18. Karagiannis I, van Lier A, van Binnendijk R, Ruijs H, Ruijs H, Fanoy E, Conyn-Van Spaendonck MA, de Melker H, Hahne S (2008) Mumps in a community with low vaccination coverage in the Netherlands. Euro Surveillance 13:24

    Google Scholar 

  19. Kay D, Roche M, Atkinson J, Lamden K, Vivancos R (2011) Mumps outbreaks in four universities in the North West of England: prevention, detection and response. Vaccine 29:3883–3887

    Article  PubMed  CAS  Google Scholar 

  20. Kuzmanovska G, Polozhani A, Mikik V, Stavridis K, Aleksoski B, Cvetanovska Z, Binnendijk R, Bosevska G (2010) Mumps outbreak in the former Yugoslav Republic of Macedonia, January 2008–June 2009: epidemiology and control measures. Euro Surveillance 15:23

    Google Scholar 

  21. Lashkari HP, El Bashir H (2010) Immunisations among school leavers: is there a place for measles-mumps-rubella vaccine? Euro Surveillance 15:17

    Google Scholar 

  22. LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S, Gargiullo P (2007) Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 161:294–301

    Article  PubMed  Google Scholar 

  23. LeBaron CW, Forghani B, Beck C, Brown C, Bi D, Cossen C, Sullivan BJ (2009) Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 199:552–560

    Article  PubMed  Google Scholar 

  24. Leineweber B, Grote V, Schaad UB, Heininger U (2004) Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubelia and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J 23:361–363

    Article  PubMed  Google Scholar 

  25. Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P (2011) Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine 29:2222–2226

    Article  PubMed  CAS  Google Scholar 

  26. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P (2010) Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. British Medical Journal 340:c1626

    Article  PubMed  CAS  Google Scholar 

  27. Leuridan E, Van Damme P (2007) Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 25:6296–6304

    Article  PubMed  CAS  Google Scholar 

  28. Manikkavasagan G, Ramsay M (2009) Protecting infants against measles in England and Wales: a review. Arch Dis Child 94:681–685

    Article  PubMed  CAS  Google Scholar 

  29. Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, Broadhead RL, Brabin BJ, Johnson PM, Hart CA (1998) Placental antibody transfer: influence of maternal HIV infection and placental malaria. ArchDisChild Fetal Neonatal Ed 79:F202–F205

    Article  Google Scholar 

  30. Nicoara C, Zach K, Trachsel D, Germann D, Matter L (1999) Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses. ClinDiagnLab Immunol 6:868–871

    CAS  Google Scholar 

  31. Okoko BJ, Wesumperuma LH, Hart AC (2001) Materno-foetal transfer of H. influenzae and pneumococcal antibodies is influenced by prematurity and low birth weight: implications for conjugate vaccine trials. Vaccine 20:647–650

    Article  PubMed  CAS  Google Scholar 

  32. Okoko JB, Wesumperuma HL, Hart CA (2001) The influence of prematurity and low birthweight on transplacental antibody transfer in a rural West African population. TropMedIntHealth 6:529–534

    CAS  Google Scholar 

  33. Oyedele OO, Odemuyiwa SO, Ammerlaan W, Muller CP, Adu FD (2005) Passive immunity to measles in the breastmilk and cord blood of some nigerian subjects. JTropPediatr 51:45–48

    Google Scholar 

  34. Park DW, Nam MH, Kim JY, Kim HJ, Sohn JW, Cho Y, Song KJ, Kim MJ (2007) Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Vaccine 25:4665–4670

    Article  PubMed  Google Scholar 

  35. Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE (2004) Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 189(Suppl 1):S116–S122

    Article  PubMed  Google Scholar 

  36. Sato H, Albrecht P, Reynolds DW, Stagno S, Ennis FA (1979) Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. AmJDisChild 133:1240–1243

    CAS  Google Scholar 

  37. Sauerbrei A, Groh A, Bischoff A, Prager J, Wutzler P (2002) Antibodies against vaccine-preventable diseases in pregnant women and their offspring in the eastern part of Germany. MedMicrobiolImmunol(Berl) 190:167–172

    CAS  Google Scholar 

  38. Siegrist CA (2001) Neonatal and early life vaccinology. Vaccine 19:3331–3346

    Article  PubMed  CAS  Google Scholar 

  39. Singh J, Khare S, Prabha S, Chandra R, Jain DC, Bhatia R, Sokhey J (1998) Transplacental transfer of measles antibody in Delhi. Indian Pediatr 35:1187–1191

    PubMed  CAS  Google Scholar 

  40. Theeten H, Hutse V, Hens N, Yavuz Y, Hoppenbrouwers K, Beutels P, Vranckx R, Van Damme P (2011) Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiol Infect 139:494–504

    Article  PubMed  CAS  Google Scholar 

  41. Vandermeulen C, Mathieu R, Leroux-Roels G, Van Damme P, Hoppenbrouwers K (2007) Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 25:6672–6676

    Article  PubMed  Google Scholar 

  42. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K (2004) Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 22:2713–2716

    Article  PubMed  Google Scholar 

  43. Verbeke M (2000) Linear Mixed Models for Longitudinal Data. Springer Verlag, New York

    Google Scholar 

  44. Wesumperuma HL, Perera AJ, Pharoah POD, Hart CA (1999) The influence of prematurity and low birthweight on transplacental antibody transfer in Sri Lanka. Ann Trop Med Parasitol 93:169–177

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by an ESPID Grant Award. EL receives a research grant from the Faculty of Medicine, University of Antwerp, for a PhD study on maternal antibodies against vaccine-preventable diseases. Some of the study's nursing activities were sponsored by GSK Belgium, Genval. NG is beneficiary of a postdoctoral grant from the AXA Research Fund. The work of NH has been funded by “SIMID”, a strategic basic research project funded by the institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), project number 060081 and by the IAP research network nr P6/03 of the Belgian Government (Belgian Science Policy). PVD acts as (principal) investigator for vaccine trials conducted on behalf of the University of Antwerp, for which the University obtains research grants from vaccine companies.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, WHO Collaborating Centre for Control and Prevention of Infectious Diseases, University of Antwerp, UA-CDE-R 2.13, Universiteitsplein 1, 2610, Wilrijk, Antwerp, Belgium

    E. Leuridan & P. Van Damme

  2. Interuniversity Institute for Biostatistics and statistical Bioinformatics, Hasselt University, Hasselt, Belgium

    N. Goeyvaerts & N. Hens

  3. Centre for Health Economics Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, WHO Collaborating Centre for Control and Prevention of Infectious Diseases, University of Antwerp, Antwerp, Belgium

    N. Goeyvaerts & N. Hens

  4. National Reference Center for Measles and Rubella, OD Communicable and Infectious Diseases–Viral Diseases, Scientific Institute of Public Health, Brussels, Belgium

    V. Hutse

Authors
  1. E. Leuridan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Goeyvaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Hens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Hutse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Van Damme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Leuridan.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 32.6 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leuridan, E., Goeyvaerts, N., Hens, N. et al. Maternal mumps antibodies in a cohort of children up to the age of 1 year. Eur J Pediatr 171, 1167–1173 (2012). https://doi.org/10.1007/s00431-012-1691-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-012-1691-y

Keywords

Search

Navigation